Medulloblastoma / high risk. Radiotherapy in high risk medulloblastoma
|
|
- Blanche Williamson
- 5 years ago
- Views:
Transcription
1 Radiotherapy in high risk medulloblastoma PROS Meeting London October 2012 Reference Centre for Radiotherapy, Dept. for Radiation Oncology University of Leipzig Johannisallee 34, Leipzig/Germany Phone: R.-D. Kortmann Co-Workers: A. Klein; A. Lehmann, Dr.rer.nat. S. Klagges, Dr. med. K. Müller
2 2. Posterior fossa (subclinical disease high risk?) Medulloblastoma / high risk Areas at risk 1. Leptomeningeal space (subclinical disease / low risk ) 3. Tumour site (residual tumour R1-2) tumour SSD 100 cm SSD 100 cm rotation of collimator according to divergence angle of upper spinal field isocentre Spinal canal SSD : source to skin distance
3 HIT 91 / relapse free survival with respect to risk profile M0 versus M2/3 1 0, (+/- 0.06) 0, (+/- 0.09) 0,4 0,2 0 p < (+/- 0.15) no residual tumour (n=82) residual tumour (n=36) M 2/3 (n=19) 0 0,5 1 1,5 2 2,5 3 3,5 4 4,5 5 5,5 6 relapse-free survival (years) Kortmann et al., 2000
4 SFOP high risk / chx, RT 35-36Gy / 55 56Gy, maint.-chx. Event free / overall survival pat. EFS Res. tu. only % M % M % P = 0.12 n.s. Verlooy et al., 2006
5 M1 versus M 2 3
6 high risk (M1-3) St. Jude / retrospective analysis 5 year EFS M0 80.5% M1 60.6% M2/M3 41.8% Sanders et al., 2008
7 CCG 921 / phase III (immediate RT versus sandwich chx. / RT) M0, n = 86 M1, n = 31 M2+, n = 51 (M0 v M1 v M21) (P =.0006). Zeltzer et al., 1999
8 HIT 91 / overall survival with respect to immediate or delayed RT / M1 10 year EFS 10 year OS Maintenance 17 71% (±11) 70% (±12) Sandwich 16 36% (±12) 34% (±12) Timing of RT in M 1 Von Hoff et al., 2009
9 MET- HIT 2000 ab 4 M1sig-M years 2 x HIT SKK / RT hfx (2x1.0Gy) 40Gy CSA, boosts 50-68Gy, 4 x Packer Interim analysis M2/3 M 1 arm discontinued -> switch back to HIT 91 / maintenance M1
10 HIT 91 versus HIT 2000 / PFS with respect to immediate or delayed RT / M1 M1: PFS (since diagnosis) HF versus HIT 91 Interimanalysis - 09/12 HIT 91 Immediate RT (CSA 35.2 / PF : 55 Gy) Followed by 8 x CCNU, Cispl., VCR ( Packer ) HIT 2000 ab 4 M1sig-M years 2 x HIT SKK / RT hfx (2x1.0Gy) 40Gy CSA, boosts 50-68Gy, 4 x Packer
11 Is there a dose response relationship for high risk disease (M1-3)?
12 SIOP II / M2-3 / event - free survival and overall survival High risk patients (metastases versus no metastases) (Standard dose RT : 35 Gy / 55 Gy) 5 year EFS no pre RT chx : 52.8% 5 year EFS pre RT chx. : 56.3% p=n.s EFS : ca 65% No metastases / n = 87 EFS : ca 40% Pat. +/- pre RT chx. EFS data not given in publication Metastases / n = 29 All patients received maintenance chx. Bailey et al., 1995
13 SIOP III / M2-3 / event - free survival and overall survival 4 cycles chx followed by RT CSA : 5 x 1.67 Gy / 35 Gy Boost PF : 55 Gy Boost metastases Gy n = 68 pat. 3 years 5 years EFS 39.7% 34.7% OS 50.0% 43.9% Taylor et al., 2005
14 SFOP high risk / chx, RT 35-36Gy / 55 56Gy, maint.-chx. Event free / overall survival 115 pat. (3-18 years) High risk : residual tumour only / M1-3) 5 year EFS : 49.8% OS : 60% pat. EFS Res. tu. only % M % M % Verlooy et al., 2006
15 High risk MB (larger residual tumour or / M1 or M2 3 Event free survival CSA 39.6 Gy /55.8Gy, boost to metast. if M2/3 (33 / 42 pat.) M1 M2 M3 9 pat. 6 pat. 27 pat. Group pat. 3 year 5 year Average 86 87% 83% High 48 75% 70% M % Log-rank p = Gajjar et al., 2006
16 high risk / INT Mailand (n = 28 patients) Int. chx. followed by hyperfractionated accelerated RT / HART CSA : 2 x 1.3 Gy, 39 Gy (> 10 y.) 31.2 (<10y) Boost PF : 60 Gy (> 10 y.) 59.7 (< 10 y) Boost metast. 2 x 1.5 Gy, 9 Gy 5-year EFS : 70% PFS : 72% OS : 73% Gandola et al., 2009
17 HIT 2000 / PFS for RT-Duration <= 50 days vs. > 50 days, n=61 patients with 68,0 Gy, only M2/3; n = 22 events Interimanalysis - 09/12 HIT 2000 ab 4 M1sig-M years 2 x HIT SKK / RT hfx (2x1.0Gy) 40Gy CSA, boosts 50-68Gy, 4 x Packer
18 HIT 2000 / PFS for RT- dose <= 66 Gy vs. > 66 Gy n=92 patients, only M2/3; n = 35 events Interimanalysis - 09/12 HIT 2000 ab 4 M1sig-M years 2 x HIT SKK / RT hfx (2x1.0Gy) 40Gy CSA, boosts 50-68Gy, 4 x Packer
19 HIT 2000 (protocol) versus HIT 91 (non-protocol) only M2/3 / PFS Interimanalysis - 09/12
20 high risk (M2-3) Outcome in prospective series / dose prescription (all protocols contained chemotherapy) Author/study Pat. dose outcome Prados et al., 1996 M1-3: 15 24/54 Gy /boosts 5 year PFS 21% CCG Evans et al., 1996 M2 : 15 M3 : 8 35/55 Gy / boosts 5 year EFS : 20% 57% CCG Zeltzer et al., 1999 M2/3 : 49 35/55 Gy / boosts 5 year PFS : 40% PNET II Bailey et al., /55 Gy/boosts ca 40% PNET III Taylor et al., /55 Gy /boosts 5 year EFS : 34.7% HIT 91 Kortmann et al., /55 Gy / boosts 3 year EFS : 30% SFOP Verlooy et al., /55-56Gy / boosts 5 year EFS : 43.1% INT Milano Gandola et al, /60 Gy hfx acc Boosts 9 Gy (9 pat. M1) 5 year PFS : 72% HIT 2000 (interim analysis) 90 40/68Gy / Boosts 50-68Gy 4 year EFS : 65% Gajjar et al., /55.8Gy / Boosts (9 pat. M1) 66% POG 9031, 2000 Abstract /55.8Gy Boosts 3 year EFS M2: 67%, M3: 66%
21 Radiochemotherapy for high risk disease (M1-3)?
22 high risk (M1-3) carboplatin during CSA (COG Phase I/II Study) OS and PFS / central review / regimen A CSA : 36 Gy / PF 55.8 Gy Boost : Gy Jakacki et al., 2012
23 high risk (M1-3) carboplatin during CSA (COG Phase I/II Study) OS and PFS / central review / regimen A and B CSA : 36 Gy / PF 55.8 Gy Boost : Gy Jakacki et al., 2012
24 high risk (M1-3) carboplatin during CSA (COG Phase I/II Study) OS / central review / M stage CSA : 36 Gy / PF 55.8 Gy Boost : Gy Jakacki et al., 2012
25 high risk (M1-3) carboplatin during CSA (COG Phase I/II Study) PFS and OS / central review / anaplasia CSA : 36 Gy / PF 55.8 Gy Boost : Gy Jakacki et al., 2012
26 Stratification Biological Markers (M1-3)?
27 Biological markers high risk (M + versus M 0)
28 WNT / overall survival / M + versus M 0 97% : classic subtype 9% M + (n = 6 -?-, details not mentioned) M + only children Total : 68 pat. moderate RT concept in WNT M +? Kool, et al., 2012
29 Conclusions M 1 PFS / OS better than M 2 /3 - timing (immediate RT?) M 2/3 Dose response relationship - HART (Italy) : excellent outcome (however : only few patients) - HIT POG 9031 / St. Jude experience Overall treatment time (?) Open question : timing (immediate RT, chx. protocol?) role of acceleration (HART)? M 1-3 Role of concurrent radio-chemotherapy (COG protocol)? Role of biological markers? - stratification of treatment survival benefit 20-30%? (WNT : moderate RT concept?)
30 Thank you very much for your attention Leipzig Sponsored by the Deutsche Kinderkrebsstiftung Reference Centre for Radiotherapy, Dept. for Radiation Oncology University of Leipzig Johannisallee 34, Leipzig/Germany Phone: R.-D. Kortmann / Co-Workers: A. Klein; A. Lehmann, Dr.rer.nat. S. Klagges, Dr. med. K. Müller
High grade glioma + brainstem glioma
+ brainstem glioma Highly agressive tumours Median survival ca 9-12 months Curative or palliative treatments? Intensity of treatment Side effects Quality of life issues + brainstem glioma Aims of radiotherapy
More informationIntracranial AT RT / radiotherapy. Therapeutic dilemma / radiotherapy
Therapeutic dilemma / radiotherapy Agressive tumour, poor outcome Past treatments based on MB concepts (RT CSA) MB Overall survival Mean age : 6.52 years n=36, 5 year 75% 1. Tumour occurs in the very young
More informationHIT-MED Guidance for Patients with newly diagnosed Medulloblastoma Ependymoma CNS Embryonal Tumour * and Pineoblastoma
HIT-MED Guidance for Patients with newly diagnosed Medulloblastoma Ependymoma CNS Embryonal Tumour * and Pineoblastoma Version 4.0 Attention: The guidance given here describes current treatment strategies
More informationA PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA
A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA HIT SIOP PNET 4 A SIOP and GPOH TRIAL START DATE 1 st September
More informationProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
1 von 9 10.12.2013 09:03 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: UKM08_0057 Previous Study Return to List Next Study Prospective Trial for the Diagnosis and Treatment
More informationEvolving of Therapeutic Strategies for CNS-PNET
Evolving of Therapeutic Strategies for CNS-PNET Pediatr Blood Cancer 2013;60:2031 2035 Maura Massimino, MD, 1 * Lorenza Gandola, MD, 2 Veronica Biassoni, MD, 1 Filippo Spreafico, MD, 1 Elisabetta Schiavello,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MEDULLOBLASTOMA AND PNET CNS Site Group Medulloblastoma and PNET Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION
More informationHimmelfarb Health Sciences Library, The George Washington University. Neurology Faculty Publications
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Neurology Faculty Publications Neurology 12-2012 Radiation therapy quality in CCG/POG intergroup 9961:
More informationTreatment of Recurrent. Central Nervous System. Primitive Neuroectodermal Tumours (PNETs) in Children and Young People. Version 1.
Treatment of Recurrent Central Nervous System Primitive Neuroectodermal Tumours (PNETs) in Children and Young People Version 1.0 September 2011 Barry Pizer on behalf of the CCLG CNS Interest Group Guidance
More information7/1/2015. Radiotherapy in Infant Brain Tumors. Goals and Objectives. Primary Brain and CNS Tumors (0-14 years) Brain Tumors (1 to 4 years)
Radiotherapy in Infant Brain Tumors ARNOLD C. PAULINO, M.D. PROFESSOR OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER AND TEXAS CHILDREN S HOSPITAL Radiotherapy in Infant Brain Tumors 1. Try to Avoid Irradiation
More informationState of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center
State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech
More informationCase Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
Oncology Volume 2009, Article ID 247873, 4 pages doi:10.1155/2009/247873 Case Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
More informationChemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Chemotherapy for Childhood and Primitive Neuroectodermal Tumors ROGER J. PACKER, a JONATHAN L. FINLAY b a Department of Neurology, Children s National Medical Center, Washington DC, USA; b Departments
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM EPENDYMOMA Last Revision Date July 2015 1 CNS Site Group Ependymoma Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2.
More informationChildhood Liver Tumours The SIOPEL experience. Giorgio Perilongo, Clinica Pediatrica, Dipartimento A.I. Di Pediatria di Padova
Childhood Liver Tumours The SIOPEL experience Giorgio Perilongo, Clinica Pediatrica, Dipartimento A.I. Di Pediatria di Padova On behalf of the International Childhood Liver Tumour Strategy Group - SIOPEL
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationIAN CROCKER = TIM HOWARD
Winship Cancer Institute of Emory University Radiation as Consolidation in the Treatment of Newly Diagnosed CNS Lymphoma versus After Failure of Chemotherapy Pro: Upfront Radiation Ian Crocker MD, FACR,
More informationEpendymoma Programme Synopsis
Ependymoma Programme Synopsis TITLE SPONSOR PROTOCOL NUMBER EUDRACT NUMBER NATIONAL INVESTIGATOR- COORDINATOR SIOP Ependymoma program II: An International Clinical Program for the diagnosis and treatment
More informationRare Brain and CNS Tumours Guidelines
Rare Brain and CNS Tumours Guidelines In collaboration with the National Cancer Action Team Guidelines on the diagnosis and management of Adult PNETs Officers of the British Neuro-Oncology Society: President:
More informationSYNOPSIS PROTOCOL N UC-0107/1602
SYNOPSIS PROTOCOL N UC-0107/1602 A) TRIAL IDENTIFICATION SPONSOR PROTOCOL CODE NUMBER: UC-0107/1602 VERSION (NR & DATE): 0.1, MARCH 2016 TRIAL TITLE: Extracranial Stereotactic Body Radiation Therapy (SBRT)
More informationEpidemiology, Management and Treatment Outcome of Medulloblastoma in Singapore
314 Original Article Epidemiology, Management and Treatment Outcome of Medulloblastoma in Singapore Mei-Yoke Chan, 1 MBBS, MMed (Paeds), MRCP (UK), Wan-Yee Teo, 2 MBBS, Wan-Tew Seow, 3 MBBS, FRACS (Neurosurg),
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationTreatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI)
Treatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI) Tagreed AL-ALAWI Medical Physicist King Abdullah Medical City- Jeddah Aim 1. Simplify and standardize
More informationBrain Tumors in Children
Brain Tumors in Children Michael A. Grotzer University Children s Hospital of Zurich, Switzerland Incidence of Childhood Cancer CNS Tumors Acute lymphoblastic Leukemia Neuroblastoma Non-Hodgkin Lymphoma
More informationHigh dose chemotherapy in Ewing sarcoma. Nathalie Gaspar Gustave Roussy Cancer Campus, Villejuif (France)
High dose chemotherapy in Ewing sarcoma Nathalie Gaspar Gustave Roussy Cancer Campus, Villejuif (France) Principles of high-dose chemotherapy Log-linear dose/efficacy relation of alkylating agents - Increased
More informationCCLG GUIDELINES FOR STANDARD RISK MEDULLOBLASTOMA (FOR CHILDREN 3 YEARS OF AGE AND OLDER) Version 2.0 January 2011
CCLG GUIDELINES FOR STANDARD RISK MEDULLOBLASTOMA (FOR CHILDREN 3 YEARS OF AGE AND OLDER) Version 2.0 January 2011 Barry Pizer Heidi Traunecker Frank Saran On behalf of the CCLG PNET Group 1 CONTENTS 1.0
More informationPrimary pineal tumors: outcome and prognostic factors a study from the Rare Cancer Network (RCN)
Primary pineal tumors: outcome and prognostic factors a study from the Rare Cancer Network (RCN) Salvador Villà, Robert C. Miller, Marco Krengli, Huda Abusaris, Brigitta G. Baumert, Stephanie Servagi-Vernat,
More informationKey Words. Infants Brain tumors Chemotherapy Radiation therapy
The Oncologist The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Pediatric Oncology Current
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) Outcomes Across Three Decades of Diagnosis Working Group and Investigators: This
More information19(4), , 2017 doi: /neuonc/now234 Advance Access date 23 December 2016
576 Neuro-Oncology 19(4), 576 585, 2017 doi:10.1093/neuonc/now234 Advance Access date 23 December 2016 Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma:
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationCurrent Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular
More informationAdult neuroectodermal tumours of posterior fossa (Medulloblastoma) and of supratentorial sites
1 di 21 10/01/2011 9.11 Adult neuroectodermal tumours of posterior fossa (Medulloblastoma) and of supratentorial sites 1. GENERAL INFORMATION 2. PATHOLOGY AND BIOLOGY 3. DIAGNOSIS 4. STAGING 5. PROGNOSIS
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM GERM CELL TUMOURS CNS Site Group Germ Cell Tumours Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationApproximately 5% of pediatric brain tumors arise
Neuro-Oncology 13(6):680 689, 2011. doi:10.1093/neuonc/nor045 NEURO-ONCOLOGY Thalamic high-grade gliomas in children: a distinct clinical subset? Christof M. Kramm, Sandra Butenhoff, Ulrike Rausche, Monika
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: James RD, Glynne-Jones R, Meadows HM, et al.
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationCNS Metastases in Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer CNS Metastases in Breast Cancer CNS Metastases in Breast Cancer Version 2006: Maass / Junkermann Version 2007 2009: Bischoff
More informationCountry Presentations of FNCA FY2007 Workshop on Radiation Oncology
Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Annex 3 Country presentations on CERVIX-III -China: Total Patients: 18, 8 alive: 1 with metastasis lung, another one metastasis to liver;
More informationThe technique of craniospinal irradiation of paediatric patients in supine position
The technique of craniospinal irradiation of paediatric patients in supine position Pavel Šlampa 1, Zuzana Seneklova 1, Jiri Simicek 1, Renata Soumarova 1, Petr Burkon 2, Ludmila Burianova 2 1 Masaryk
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationCarol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU JL is a 8 year old boy who presented with coordination problems in using his right hand (difficulty tying his shoes) in January 2011. Imaging revealed
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cns_embryonal_tumors
More informationExploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future
Exploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future Daniel Gasic Disclosure Nothing to disclose Introduction Background
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationEpendymomas: Prognostic Factors and Outcome Analysis in a Retrospective Series of 33 Patients
ORIGINAL ARTICLE Brain Tumor Res Treat 2017;5(2):70-76 / pissn 2288-2405 / eissn 2288-2413 https://doi.org/10.14791/btrt.2017.5.2.70 Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationBackground. Paediatric cancer. Leukaemia
66 9. Paediatric cancer Background Radiotherapy (RT) is an important modality of therapy in the local control of paediatric malignancies and the majority of paediatric tumours are radiosensitive. However,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationEVIDENCE BASED MANAGEMENT FOR Paediatric Brain tumours
EVIDENCE BASED MANAGEMENT FOR Paediatric Brain tumours In children, tumours of the central nervous system comprise 20% of all tumours and are second most common after leukaemia. Unlike adults, almost half
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationThe therapy of infantile malignant brain tumors: current status?
Journal of Neuro-Oncology (2005) 75: 279 285 Ó Springer 2005 DOI 10.1007/s11060-005-6752-x Childhood Brain Tumors The therapy of infantile malignant brain tumors: current status? Chantal Kalifa and Jacques
More informationSpinal Cord Doses in Palliative Lung Radiotherapy Schedules
Journal of the Egyptian Nat. Cancer Inst., Vol. 8, No., June: -, 00 Spinal Cord Doses in Palliative Lung Radiotherapy Schedules HODA AL-BOOZ, FRCR FFRRCSI M.D.* and CAROL PARTON, Ph.D.** The Departments
More informationavailable at journal homepage:
E U R O P E A N J O U R NA L O F CA N C E R46 (21) 12 133 available at www.sciencedirect.com journal homepage: www.ejconline.com Primary postoperative chemotherapy without radiotherapy for treatment of
More informationLessons from treatment of pediatric sarcomas at difficult sites. Dr. Andrea Ferrari Pediatric Oncology Unit Istituto Nazionale Tumori, Milan, Italy
Lessons from treatment of pediatric sarcomas at difficult sites Dr. ndrea Ferrari Pediatric Oncology Unit stituto Nazionale Tumori, Milan, taly Disclosure slide have no potential conflicts of interest
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationMedulloblastoma: Conventional Radiation Therapy in Comparison to Chemo Radiation Therapy in The Post-operative Treatment of High-Risk Patients
Journal of the Egyptian Nat. Cancer Inst., Vol. 17, No. 4, December: 301-307, 2005 Medulloblastoma: Conventional Radiation Therapy in Comparison to Chemo Radiation Therapy in The Post-operative Treatment
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationRadiation is an Important Component of Multimodality Therapy for Pediatric Supratentorial Non-Pineal Neuroectodermal Tumors
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 5-6-2009 Radiation is an Important Component of Multimodality Therapy
More information1 Department of Pediatric Hematology and Oncology, University. 3 Department of Pediatrics, University of Erlangen, Erlangen,
Pediatr Blood Cancer 2011;57:978 985 Frequency, Risk-Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationSYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS
SYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS María E. Echevarría, MD Assistant Professor University of Puerto Rico Medical Sciences Campus DISCLOSURES No disclosures INTRODUCTION Pediatric CNS
More informationThe Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer
Evidence-based Series # 7-13-3 EDUCATION AND INFORMATION 2013 The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Members of the Lung Cancer
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Anal Cancer Valencia May 2018 Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker: Roche, Merck Serono,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationSpatially Fractionated Radiation Therapy: GRID Sponsored by.decimal Friday, August 22, Pamela Myers, Ph.D.
Spatially Fractionated Radiation Therapy: GRID Sponsored by.decimal Friday, August 22, 2014 Pamela Myers, Ph.D. Introduction o o o o o Outline GRID compensator Purpose of SFRT/GRID therapy Fractionation
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Role of post-operative radiation therapy in single brain metastasis from clear cell sarcoma in children: a case report with systemic review Fadoua Rais, Naoual Benhmidou,
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationImproved Survival after Gross Total Resection of Malignant Gliomas in Pediatric Patients from the HIT-GBM Studies
Improved Survival after Gross Total Resection of Malignant Gliomas in Pediatric Patients from the HIT-GBM Studies CHRISTOF M. KRAMM 1, SABINE WAGNER 2, STEFAN VAN GOOL 3, HANSJÖRG SCHMID 4, RONALD STRÄTER
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationWilms Tumor Outcomes at a Single Institution and Review of Current Management Recommendations
Wilms Tumor Outcomes at a Single Institution and Review of Current Management Recommendations Background: The Duval County Medical Society (DCMS) is proud to provide its members with free continuing medical
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationMedulloblastoma is the most common malignant brain
CLINICAL AND LABORATORY OBSERVATIONS Chronic Residual Lesions in Metastatic Medulloblastoma Patients Iris Fried, MD,*w Annie Huang, MD, PhD,* Ute Bartels, MD,* Uri Tabori, MD,* Normand Laperriere, MD,z
More informationAllan Price NHS Lothian, Edinburgh, UK
Allan Price NHS Lothian, Edinburgh, UK Radiotherapy Dose Volume Timing Technique PCI Surgery Systemic agents 1 Study Dose Time Induction CT Ann Arbor 65.1-75.6 Gy Duke 73.6-80 Gy RTOG 77.4 Gy 74 Gy 6.5-7.5
More informationProfessor and Head Division of Radiation Oncology Stellenbosch University and Tygerberg Hospital Cape Town South Africa
STAGE III NONSMALL CELL LUNG CANCER TREATMENT APPROACHES WE LIKE TO PRACTICE... ALMOST UNETHICALLY Branislav Jeremic, MD, PhD Professor and Head Division of Radiation Oncology Stellenbosch University and
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationRT +/- Surgery. Concurrent ChemoRT +/- Surgery
Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More information7/1/2015. Objectives. Host Factors LATE EFFECTS OF RADIOTHERAPY IN CHILDHOOD CANCER. Chronic Conditions in Adult Survivors
LATE EFFECTS OF RADIOTHERAPY IN CHILDHOOD CANCER ARNOLD C. PAULINO, M.D. PROFESSOR DEPARTMENT OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER Objectives At the end of the presentation, the participant
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More information